Long-term Efficiency of Percutaneous Transluminal Septal Myocardial Ablation for Treating the Patients With Hypertrophic Obstructive Cardiomyopathy
10.3969/j.issn.1000-3614.2015.08.010
- VernacularTitle:经皮室间隔心肌化学消融术治疗肥厚型梗阻性心肌病的远期疗效
- Author:
Liwen LIU
;
Xingxing LI
;
Ruoxi GU
;
Xiaozeng WANG
;
Quanmin JING
;
Geng WANG
;
Xin ZHAO
;
Yaling HAN
- Publication Type:Journal Article
- Keywords:
Hypertrophic obstructive cardiomyopathy;
Percutaneous transluminal septal myocardial ablation;
Long-term efifcacy
- From:
Chinese Circulation Journal
2015;(8):757-761
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the long-term efifciency of percutaneous transluminal septal myocardial ablation (PTSMA) for treating the patients with hypertrophic obstructive cardiomyopathy (HOCM).
Methods: A total of 66/94 (70.2%) HOCM patients received PTSMA in Shenyang PLA general hospital from 2001-10 to 2012-10 were retrospectively studied. The left ventricular out lfow gradient (LVOFG) was measured at before and after the operation, ECG and echocardiography were examined at 1 month, 6 months and 1 year after operation, and then examined once per year for (63.8±28.5) months.
Results: There were 26 patients lost contact during follow-up period, 40 returned to routine clinical check-up and 2 patients died thereafter, 1 because of sudden death and 1 because of cerebral bleeding. The pre-operative average LVOTG was (102.7 ± 47.5) mmHg, compared with the values at 6 months post-operation and long term (>6 months) after operation (33.9 ± 30.2) mmHg and (29.7 ± 25.4) mmHg,P<0.001. The pre-operative average inter ventricular septal (IVS) was (20.1 ± 3.6) mm, compared with the values at 6 months post-operation and long term after operation (17.5 ± 2.9) mm and (16.4 ± 3.6) mm, P=0.028 andP<0.001. There were 7 patients with NYHA class at II-III and having occasional chest suppression and short of breath. There were no heart transplantation, frequent premature ventricular contraction, tachycardia and other malignant arrhythmia occurred in 38 survivors.
Conclusion: PTSMA may reduce LVOTG, IVS thickness and improve the clinical symptoms in HOCM patients, the long-term efifcacy is reliable.
